biostudies-literatureIlyas SINIDDK NIH HHS5892-5905https://www.ebi.ac.uk/biostudies/studies/S-EPMC5814182biostudies-literatureUnknown9(5)Deregulated Hippo pathway signaling is associated with aberrant activation of the downstream effector yes-associated protein (YAP), an emerging key oncogenic mediator in cholangiocarcinoma (CCA). In our prior work, we have demonstrated that biliary transduction of YAP along with Akt as a permissive factor induces CCA in mice. To further delineate the mechanisms associated with YAP-associated biliary oncogenesis, we have established seven malignant murine cell lines from our YAP-driven murine CCA model. These cells express the CCA markers SRY (Sex Determining Region Y)-Box 9 (SOX9), cytokeratin (CK)-7 and 19 but lack hepatocyte nuclear factor 4 alpha and alpha-smooth muscle actin, markers of hepatocellular carcinoma and cancer-associated fibroblasts, respectively. Notably, the murine CCA ceOncotargetYAP-associated chromosomal instability and cholangiocarcinoma in mice.PMC5814182R56 DK059427P30 DK084567R01 DK059427Ilyas SISmoot RLGores GJHirsova PBronk SFKrishnan AFischbach SRVasmatzis GDhanasekaran RSmadbeck JBfalseYAP-associated chromosomal instability and cholangiocarcinoma in mice.Deregulated Hippo pathway signaling is associated with aberrant activation of the downstream effector yes-associated protein (YAP), an emerging key oncogenic mediator in cholangiocarcinoma (CCA). In our prior work, we have demonstrated that biliary transduction of YAP along with Akt as a permissive factor induces CCA in mice. To further delineate the mechanisms associated with YAP-associated biliary oncogenesis, we have established seven malignant murine cell lines from our YAP-driven murine CCA model. These cells express the CCA markers SRY (Sex Determining Region Y)-Box 9 (SOX9), cytokeratin (CK)-7 and 19 but lack hepatocyte nuclear factor 4 alpha and alpha-smooth muscle actin, markers of hepatocellular carcinoma and cancer-associated fibroblasts, respectively. Notably, the murine CCA ce2018-01-01T00:00:00Z2018 Jan2026-04-28T23:07:36.438Z2019-03-26T23:03:57ZS-EPMC58141822946404210.18632/oncotarget.23638